Metabolic Study for Heart Failure

Recruiting in Palo Alto (17 mi)

Overseen ByRichard E Pratley, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: AdventHealth Translational Research Institute

No Placebo Group

Trial Summary

What is the purpose of this trial?The purpose of the research is to help researchers understand changes in metabolism in patients that develop heart failure.

Eligibility Criteria

This trial is for adults aged 19-89 with chronic heart failure who can consent to participate. They must be scheduled for certain heart procedures, like LVAD implantation or cardiac transplantation. People with a life expectancy under 2 weeks, severe kidney disease, active infections, substance abuse, or other specific health issues cannot join.

Inclusion Criteria

Subjects are capable of giving informed consent

You are between 19 and 89 years old.

You have been diagnosed with chronic heart failure.

+3 more

Exclusion Criteria

You are not expected to live for more than 2 weeks.

You have cancer, severe kidney disease, active infection, liver damage, or alcohol or drug addiction.

Your heart has been severely damaged by a heart attack with little healthy heart tissue left.

+1 more

Participant Groups

Researchers are collecting and studying discarded heart tissue from patients undergoing various heart-related medical procedures. The goal is to understand metabolic changes in those with heart failure.

1Treatment groups

Experimental Treatment

Group I: Cardiac surgeryExperimental Treatment1 Intervention

Subjects will be recruited by a coordinator through electronic medical record (EMR) searches to identify those undergoing left ventricle assist device (LVAD) implantation and explantation, heart transplant, valve replacement or repair, endomyocardial biopsy during catheterization, and arterial bypass surgery. Prior to the procedure, potential subjects will be informed about the clinical study and if interested, they will be consented.